A drug development platform for immunogenicity and toxicity assessment using advanced multi-omic profiling
Manon Scholaert1,2, Mathias Peries2, Emilie Braun2, Alexandra Ochando3, Emeline Pagès2 and Nicolas Gaudenzio1,2
1Toulouse Institute for Infectious and Inflammatory Diseases (Infinity) INSERM UMR1291 – CNRS UMR5051 – University Toulouse III, France, 2Genoskin SAS, Toulouse, France, 3Genoskin Inc, Salem MA, USA
Longitudinal maintenance of human skin viability in HypoSkin®
Evaluating local immune responses to injectable therapeutics remains challenging, highlighting the need for human-relevant models that preserve native skin architecture and resident immune cells.
Genoskin’s HypoSkin® is an immunocompetent human ex vivo skin model preserving the epidermis, dermis, and hypodermis, enabling the investigation of intradermal and subcutaneous injections under controlled conditions.
Presented at SOT 2025, this study demonstrated preserved skin architecture over 7 days and stable transcriptomic profiles for up to 10 days. Following subcutaneous mRNA COVID-19 vaccine injection, multi-omic analyses revealed inflammatory responses, cytokine secretion, and gene expression changes across resident immune cell populations.
HypoSkin® provides a human-relevant platform to investigate injection site reactions, characterize immune responses, and support preclinical drug and vaccine development.
Please fill in the form below to access the full poster.
After submitting this form, you will receive an email with the link to access our poster.
Want more research like this in your inbox? Subscribe to our newsletter →
Comments are closed.